#United States #Scottsdale #Precision Medicine #Xcellerant #Geneticure

A Major Investment in Precision Medicine: Xcellerant Ventures and Geneticure

Xcellerant Ventures, a prominent venture capital firm based in Scottsdale, Arizona, has recently made headlines with its bold investment of $1 million into Geneticure, a trailblazer in precision medicine. This strategic investment is seen as a major step forward in expanding Arizona's burgeoning biotech landscape and enhancing healthcare innovation in the region.

Geneticure is leading the way in developing innovative tests aimed at predicting how patients will respond to hypertension treatments. Their groundbreaking approach involves a non-invasive cheek swab test that assesses four physiological pathways to ascertain a patient's likelihood of benefiting from renal denervation (RDN) procedures. This procedure is already FDA-approved and has the potential to serve around 35 million eligible patients across the United States. However, with over 10 million patients likely to find no significant relief from these treatments, Geneticure's technology provides valuable insights through its responder score, allowing physicians to make informed decisions about patient suitability for such interventions.

Mike Shufeldt, General Partner at Xcellerant Ventures, commented on the strategic importance of this investment. He emphasized, "Renal denervation is a game-changer, but the ability to identify the right candidates has been a critical missing link. Geneticure provides that clarity that both physicians and patients need. We are excited to support a team that has strong ties to Arizona as they develop a state-of-the-art laboratory here, fostering healthtech innovation and creating biotech jobs for the local economy."

Scott Snyder, CEO of Geneticure, also highlighted the benefits of the new investment, stating that it would enhance their clinical presence in Arizona. He noted, "Having our operations closer to clinical partners and talent will help us scale effectively. Xcellerant brings more than just capital to the table, and we look forward to collaborating with their team as we bring renal denervation responder testing to physicians and patients."

In addition to expanding their operational capabilities, Geneticure plans to utilize the investment to further advance clinical validation of their tests, refine their reimbursement strategies, and prepare for a Series A funding round. Currently, alongside their RDN platform, Geneticure possesses four U.S. patents and offers a commercial hypertension test that aids in the daily selection of medications for patients.

As Xcellerant's Fund I reaches its closure, individual investors now have the opportunity to engage with Xcellerant’s early-stage healthcare projects through the Jetstream Venture Fund (jvf.vc). This fund is designed to democratize access to venture capital investments, enabling a broader audience to participate in healthcare innovation.

About Geneticure

Geneticure operates out of Arizona and Minnesota, providing genetic tests that assist healthcare providers in predicting patient responses to various hypertension treatments. Their innovative solutions represent a leap forward in personalized medicine.

About Xcellerant Ventures

Xcellerant Ventures is a venture capital firm situated in Scottsdale, Arizona, focusing on early-stage healthcare technology companies that aim to enhance clinical outcomes while reducing healthcare costs. Their mission reflects a commitment to empowering healthtech advancements in the region, ensuring that Arizona remains on the cutting edge of biotechnology and healthcare innovation.

The investment in Geneticure signifies not only a financial commitment but also a shared vision for advancing healthcare through innovative technologies that can greatly impact patient care and the healthcare landscape as a whole.